Natco Pharma Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nfnq5mjawuejs6dimrevszce.pdf

Key Takeaways


Lenalidomide (Revlimid) Franchise

Rajeev Nannapaneni: "It will increase my friend. It will increase... it will increase to almost -- by end of the term, it will increase to almost one third of the total sale of the innovator."

Kothur Plant: FDA Inspection & Mitigation

Rajeev Nannapaneni: "Overall, I think our impact will be minimal. So I think let's wait for the classification of the inspection and we'll make a decision."

Agro-Business: Scaling With Margin Drag


Other Business Segments

SegmentTrendCommentary
Non-US formulations (Brazil, Canada)▲ Strong growthDoing extremely well; expected to grow another 25% a year; some approvals pending in the next 1–1.5 years with benefit visible in FY25.
Domestic formulations▬ StableHalf-year growth around 10–12%; organic growth expectation ~8–10%; the missing piece is an acquisition, held up by valuation discussions.
Dash Pharmaceuticals (US subsidiary)▼ Loss-makingLaunched some older products and doing reasonably well, but still losing money in its early stage; management expects it will take at least 1.5–2 years before it turns.
Semaglutide (with Viatris)▬ Early stageFiled from a CMO site for both Ozempic and Wegovy; review and patent litigation are in very early days; no timeline can be given.
Rajeev Nannapaneni: "I just found it to be very premature to give a timeline. I would refrain from doing that. Once it develops, I think we will give you some time to come. As of now, it's too premature."

Margins, Cash & Capital Allocation

Rajeev Nannapaneni: "Our job is not to do equity stock market investment. Our job is to invest in pharmaceutical research and pharmaceutical manufacturing and pharmaceutical acquisition."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year PAT guidanceINR1,000–1,200 crores; "no problem achieving it"FY24
Q3 sequential weaknessDecember quarter will not be as strong as September; agro season over, Revlimid sale not thereQ3 FY24
Q4 pickupThings will pick up again for the March quarterQ4 FY24
Agro-business revenueINR150–200 crores this year; minimum INR200 crores next year; 25% compounded growth targeted thereafterFY24 / FY25
Agro-business profitabilityExpectation of a very good profit run in the next yearFY25
Non-US geography growthBrazil and Canada expected to grow another 25% a yearOngoing
Non-US approvals benefitSome approvals pending; benefit visible in FY25, nothing before March 2024FY25
FTF filingsAnother 2–3 products in initial stage; filings in FY25, nothing in next 4–5 monthsFY25
Dash Pharmaceuticals turnaroundWill take at least 1.5–2 years before it turnsFY26–FY27
Lenalidomide market shareWill increase to almost one-third of innovator's total sale by end of termEnd of 2025
Margin sustainabilityExpect margins to sustain for at least the next couple of years based on pipelineFY25–FY26
Kothur FDA classification90-day clock started from November 8 response submissionBy ~February 2024

Key Metrics

MetricQ2 FY24
Consolidated total revenue₹1,060.8 cr, growth of roughly 134% YoY vs ₹452.6 cr
Consolidated net profit₹369 cr, over six-fold increase YoY vs ₹56.8 cr
PAT guidance for FY24₹1,000 cr to ₹1,200 cr
Brazil revenue₹34 cr in the quarter
Canada revenue₹60 cr to ₹61 cr in the quarter
Agro-business revenue₹150 cr to ₹160 cr expected this year, minimum to ₹200 cr; last year about ₹40 cr
Agro-business seasonal split60% Kharif, 40% Rabi
Domestic business growth10% to 12% half-year growth
Domestic organic growth expectation8% to 10%
R&D spend8% to 10% of revenue
Net cash level₹1,550 cr as of October 31; cash and equivalents ₹1,657 cr, foreign bill discounting borrowing ₹108 cr
Average yield on India rupee deposits7.5% to 7.75%
Cash return in offshore subsidiaries5% to 5.5%
Equity exposure5% to 6% of total cash exposure
Revlimid volume share by end of termone third of innovator's total sale, term ends by 2025 end